Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in MiaPaCa human pancreatic cancer cells

Exp Cell Res. 2002 Oct 15;280(1):90-6. doi: 10.1006/excr.2002.5625.

Abstract

Exposure of MiaPaCa cells to 1-beta-D-arabinosylcytosine (ara-C) resulted in an increase in DNA ligase levels up to threefold compared to that in the untreated control cells, despite significant growth inhibition. Increased levels of DNA ligase I protein appear to correlate with the appearance of increased mRNA levels. The [(3)H]thymidine incorporation experiment and the biochemical assay of total polymerase activity revealed that an increase in DNA ligase I levels after treatment with ara-C was not accompanied by an increase of DNA synthesis or an increased presence of DNA polymerase activity inside cells. When cells resumed DNA synthesis after drug treatment, DNA ligase I levels began to drop, indicating that increased DNA ligase I is not required for DNA synthesis. An increase in DNA ligase I was also observed in cells treated with aphidicolin, another inhibitor of DNA synthesis that inhibits DNA polymerases without incorporating itself into DNA, indicating that an increase in DNA ligase I levels could be caused by the arrest of DNA replication by these agents. Interestingly, caffeine, which is a well-known inhibitor of DNA damage checkpoint kinases, abrogated the increase in DNA ligase I in MiaPaCa cells treated with ara-C and aphidicolin, suggesting that caffeine-sensitive kinases might be important mediators in the pathway leading to the increase in DNA ligase I levels in response to anticancer drugs, including ara-C and aphidicolin. We propose that ara-C and aphidicolin induce damage to the DNA strand by arresting DNA replication forks and subsequently increase DNA ligase I levels to facilitate repair of DNA damage.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacokinetics
  • Antimetabolites, Antineoplastic / pharmacology*
  • Aphidicolin / pharmacokinetics
  • Aphidicolin / pharmacology*
  • Caffeine / pharmacology
  • Cell Count
  • Cell Division / drug effects
  • Cell Line
  • Cell Survival / drug effects
  • Cytarabine / pharmacokinetics
  • Cytarabine / pharmacology*
  • DNA Ligase ATP
  • DNA Ligases / biosynthesis*
  • DNA Ligases / genetics
  • DNA Repair / drug effects
  • DNA, Neoplasm / biosynthesis
  • DNA-Directed DNA Polymerase / analysis
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacokinetics
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Nucleic Acid Synthesis Inhibitors / pharmacology
  • Pancreatic Neoplasms / enzymology*
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / pathology
  • Phosphodiesterase Inhibitors / pharmacology
  • RNA, Messenger / metabolism
  • Tumor Cells, Cultured

Substances

  • Antimetabolites, Antineoplastic
  • DNA, Neoplasm
  • Enzyme Inhibitors
  • LIG1 protein, human
  • Nucleic Acid Synthesis Inhibitors
  • Phosphodiesterase Inhibitors
  • RNA, Messenger
  • Cytarabine
  • Aphidicolin
  • Caffeine
  • DNA-Directed DNA Polymerase
  • DNA Ligases
  • DNA Ligase ATP